The role of topotecan in cancer ginecology treatment
The high morbidity, often latent, asymptomatic disease development is not optimal therapy in the first line, causes the development of the frequent recurrence of tumors, requiring second and thirds lines of chemotherapy. The use of topotecan in standard mode is limited by myelosuppression, therefore...
Saved in:
Main Authors: | A. G. Kedrova (Author), V. V. Kosyy (Author), D. A. Astakhov (Author) |
---|---|
Format: | Book |
Published: |
ABV-press,
2017-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Micellar paclitaxel in the treatment of patients with tumors of the female reproductive system
by: A. G. Kedrova, et al.
Published: (2019) -
Chemoembolization with HepaSpheres in the treatment of recurrent pelvic tumors
by: A. G. Kedrova, et al.
Published: (2019) -
Chemoembolization with HepaSpheres as a stage of comprehensive treatment for malignant pelvic tumors
by: A. G. Kedrova, et al.
Published: (2019) -
Ovarian cancer: new accents treatment of patients with platinum-sensitive relapses
by: A. G. Kedrova, et al.
Published: (2016) -
The leadership of topotecan in the treatment of recurrent platinum-resistant ovarian cancer
by: K. E. Borisov
Published: (2014)